Recent studies have shown that a drug coated balloons (DCB) based approach resulted non inferior when compared against drug eluting stents (DES) only approach in patients with instent restenosis and de novo lesions in small vessel disease. So far, two international consensuses have reported the use of DCB is feasible and safe to treat native<a href="https://solaci.org/en/2023/02/22/should-we-use-drug-coated-balloons-in-patients-with-multivessel-disease/" title="Read more" >...</a>
Recent studies have shown that drug-eluting stents with biodegradable polymer and ultrathin struts are safe and effective, including low rates of stent thrombosis. This is why researchers conducted the BIODEGRADE (Biomatrix and Orsiro Drug-Eluting Stents in Angiographic Result in Patients With Coronary Artery Disease) study, which showed the non-inferiority at 18 months of ultrathin biodegradable polymer<a href="https://solaci.org/en/2023/02/16/biodegrade-does-stent-design-affect-long-term-clinical-results/" title="Read more" >...</a>
3 Year Clinical Outcome Analysis and Failure Predictors in the Use of Intracoronary Brachytherapy for Drug-Eluting Stent Restenosis In-stent restenosis (ISR) has been one of the greatest obstacles standing in the way of long term patency in percutaneous coronary interventions. However, the use of drug eluting stents (DES) and their development has helped reduce ISR<a href="https://solaci.org/en/2023/02/14/intracoronary-brachytherapy-for-drug-eluting-stent-restenosis/" title="Read more" >...</a>
Monotherapy in patients with complex angioplasty: meta-analysis of 5 randomized studies. Even though prolonged dual antiplatelet therapy (DAPT) might reduce the risk of important ischemic complications, this reduction will come at the expense of a significant increase of bleeding risk, which makes us reassess the cost benefit ratio of this decision. This is also why<a href="https://solaci.org/en/2023/02/10/monotherapy-with-p2y12-in-complex-interventions-less-and-less-risky/" title="Read more" >...</a>
The safety and efficacy of drug-coated balloons (DCB) has been established for the treatment of in-stent restenosis of conventional bare-metal stents (BMS) and drug-eluting stents (DES). Furthermore, these devices are also used to treat de novo coronary lesions, as demonstrated in the BASKET-SMALL 2—where DCBs were non-inferior to stents—and the DEBUT RCT trials—, where DCBs<a href="https://solaci.org/en/2023/02/07/is-using-drug-eluting-balloons-and-single-antiplatlelet-therapy-safe-for-patients-at-high-risk-for-bleeding-who-undergo-percutaneous-coronary-intervention/" title="Read more" >...</a>
A study compared pooled data of claudication and critical ischemia patients treated with stenting vs. by-pass surgery in femoropopliteal disease. The main objective of revascularization in femoropopliteal disease is to improve the quality of life and functional capacity of claudication patients who did not respond to medical treatment, and to save the affected limb in<a href="https://solaci.org/en/2023/02/07/stent-revascularization-in-femoropopliteal-disease-an-analysis-of-clustered-randomized-trials/" title="Read more" >...</a>
Left main coronary artery percutaneous coronary intervention (LMCA PCI) is a treatment option that is increasingly used in our setting. One of the reasons for choosing this therapeutic strategy is the improvements in devices and techniques. However, the long-term results of LMCA PCI are not well established. The aim of this retrospective study was to<a href="https://solaci.org/en/2023/01/31/left-main-coronary-artery-percutaneous-coronary-intervention-evolution-and-results-over-time/" title="Read more" >...</a>
At present, PCI is the preferred treatment for femoropopliteal lesions and drug coated balloons (DCB) have shown good performance. However, they have not yet been shown superior to bare-metal stents (BMS). This study compared randomized trials IN.PACT SFA I/II and IN.PACT JAPAN including 288 patients vs. the prospective Complete SE and DURABILITY II with 483<a href="https://solaci.org/en/2023/01/31/what-is-the-best-strategy-for-moderately-complex-femoropopliteal-lesions/" title="Read more" >...</a>
With the new devices (drug-eluting balloons [DEB], drug-eluting stents [DES], and atherotomes) percutaneous treatment is becoming the first line of approach for femoropopliteal disease, especially when dealing with not very long total occlusions. Randomized studies and registries on the use of drug-coated balloons (DCB) in femoropopliteal disease are currently available, but their evolution beyond 2<a href="https://solaci.org/en/2023/01/30/in-pact-study-should-we-start-using-dcbs-more-frequently-in-cases-of-femoropopliteal-disease/" title="Read more" >...</a>
This scientific article we briefly discuss the POKI technique, a new stent optimization strategy for bifurcation lesions. Coronary bifurcations represent 20 to 25% of percutaneous coronary interventions (PCI) and continue to be a real challenge at present; the different available treatment strategies are used to correct bifurcation carina after stenting seeing as incomplete strut apposition<a href="https://solaci.org/en/2023/01/27/poki-a-new-bifurcations-strategy/" title="Read more" >...</a>